Zimmer Biomet's SWOT analysis: orthopedic giant's stock navigates challenges

Zimmer Biomet (ZBH) reported Q3 2024 sales of $1.82 billion, a 4% year-over-year increase, with EPS meeting expectations at $1.74, up 5% from the prior year; however, 17 analysts have revised earnings expectations downward. The company is managing ERP implementation headwinds expected to impact annualized revenue by up to 1%, while focusing on its Long Range Plan targeting mid-single-digit revenue growth and EPS growth at 1.5 times revenue growth. ZBH's strategic acquisition of Paragon 28 aims to expand into the $5 billion Foot & Ankle Orthopedics market, but the company faces challenges including ERP disruptions, pricing pressures, and intense competition.

Analysis

Zimmer Biomet Holdings, Inc. (ZBH) presents a mixed operational and financial profile, characterized by steady mid-single-digit growth offset by significant near-term challenges. The company reported Q3 2024 sales of $1.82 billion, a 4% year-over-year increase, and an EPS of $1.74, up 5% annually, meeting consensus estimates. Despite this, 17 analysts have revised future earnings expectations downward, reflecting concerns primarily around the ongoing transition to a new Enterprise Resource Planning (ERP) system. This ERP migration, initiated in July 2024, has caused more disruption than anticipated and is projected to create a 60-80 basis point headwind on revenue in the second half of 2024, potentially impacting annualized revenue by up to 1%, particularly affecting surgical and bone cement products. Positively, ZBH maintains a strong gross margin of 71.2% and has seen favorable pricing impacts internationally for three consecutive quarters. Strategically, ZBH is focused on its Long Range Plan (LRP), which targets mid-single-digit revenue growth, EPS expansion at 1.5 times revenue growth, and free cash flow growth exceeding EPS growth by at least 100 basis points through 2026, though some moderation is expected in 2025. Growth drivers include a robust product pipeline featuring the OsseoFit Stemless Shoulder System, the ROSA Shoulder robotic application, two major knee products slated for H2 2025 launch, and the Persona revision knee implant gaining traction in EMEA. Furthermore, the $1.1 billion acquisition of Paragon 28, announced in January 2025, aims to penetrate the $5 billion Foot & Ankle Orthopedics market, enhancing portfolio diversification. The company's stock is trading near its 52-week low, which, according to InvestingPro, may indicate undervaluation. However, achieving its ambitious LRP targets will depend on navigating intense competition, potential pricing pressures, and successful execution of new product launches and the ERP system stabilization. Financial liquidity appears strong with a current ratio of 2.44, and ZBH has a 14-year history of consistent dividend payments.

Key Decisions for Investors

• Investors should closely monitor the resolution of the ERP system implementation issues and their impact on revenue and operational efficiency in the coming quarters, as this is a primary short-term overhang.
• Consider the long-term growth potential stemming from ZBH's innovative product pipeline, particularly the upcoming knee product launches in H2 2025 and the expansion into the foot and ankle market via the Paragon 28 acquisition, against the backdrop of current undervaluation signals.
• Evaluate ZBH's ability to achieve its ambitious Long Range Plan targets for revenue, EPS, and free cash flow growth, especially in light of the 17 analyst downward earnings revisions and ongoing competitive pressures in the orthopedic market.
• Given the stock's proximity to its 52-week low and mixed analyst sentiment (ranging from 'Underweight' to 'Market Outperform'), a thorough risk-reward assessment is warranted, focusing on execution risks versus potential recovery and growth catalysts.